However, that is both Wegovy 7.2mg and CagriSema (2 assets) that are competitive to Tirzepatide SURMOUNT-1 data as a placebo-adjusted weight loss of -20.1% and likely to be in commercialisation in the US in 2026 and early 2027
About the Author Scott Froum, DDS Editorial Director Scott Froum, DDS, a graduate of the State University of New York, Stony Brook School of Dental Medicine, is a periodontist in private practice at 1110 2nd Avenue, Suite 305, New York City, New York
2023 research suggests glutathione may help treat nonalcoholic fatty liver disease thanks to its antioxidant properties and potential to detoxify
Saliva is essential for neutralizing acids, washing away bacteria, and protecting enamel
Of the 242 vaccines, 49 are currently in widespread use for COVID-19 immunization (11 approved by the WHO and 38 approved only in a few countries), and one was withdrawn after initial approval
He has also held senior editorial roles at CNN, The Times and The Sunday Times